Vibhudutta Awasthi, Ph.D.

Professor and Associate Dean for Research

Pharmaceutical Sciences

Phone (405) 271-6593 x47331

Fax (405) -271-7505

Office CPB 309



My research interests are in the development of radiopharmaceuticals, small animal imaging and use of radiological imaging techniques to answer physiological questions. My current research focuses on the development of liposome encapsulated hemoglobin as an artificial oxygen carrier and he is studying cerebral oxygen metabolism using positron emission tomography. I am a board certified nuclear pharmacist with expertise in areas related to drug delivery, formulation development, nuclear pharmacy and small animal nuclear imaging.

Publications & Presentations

1 2 3 4 > >>
    1. Awasthi V, Gali H, Hedrick A, Da H, Eeda V, Jain D. Positron Emission Tomography (PET) with 18F-FGA for Diagnosis of Myocardial Infarction in a Coronary Artery Ligation Model. Molecular Imaging. 2022; 2022

    2. Awasthi S, Kumar G, Ramani V, Awasthi V, Rodgers K K, Xie J, Beierle J, Kyere-Davies G, Singh B, Rahman N, Chowdhury A A, Chataut N. Mechanism of Anti-Inflammatory Activity of TLR4-Interacting SPA4 Peptide. ImmunoHorizons. 2021; 5 : 659-674

    3. Awasthi V, Bulotta S, Cosco D. Bypassing the Biological Barriers by Means of Biocompatible Drug Delivery Systems. Front. Pharmacol. - Experimental Pharmacology and Drug Discovery. 2021; 12 : 801383

    4. Eeda V, Hedrick A, Awasthi V. Design of 99mTc-labeled Zinc-chelating imaging Probe for SPECT imaging of the pancreas. Bioorg Med Chem Lett. 2021; 52 : 128385

    5. Awasthi V, Eeda V. ). A Catalyst-Free and Scalable Process for Synthesis of Novel MAP4K4 Inhibitor DMX-5804 and its Glyco-Conjugates. Organic Process Research & Development. 2021; 25 : 1658–1663

1 2 3 4 > >>


1 2 >>
    1. Developing PPARγ acetylation inhibitor for the treatment of aging-related conditions. NIH. Start Date: 2021. End Date: 2026.

    2. Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment. NIH. Start Date: 2021. End Date: 2026.

    3. Surfactant protein-A regions as TLR4-immunomodulators. NIH. Start Date: 2017. End Date: 2022.

    4. Development of Bioactive Peptides for the Inhibition of Neuroinflammation and Neurotoxicity Induced by Amyloid-beta. Non-federal. Start Date: 2020. End Date: 2021.

    5. Pharmacotherapy of Traumatic Brain Injury Accompanied by Hemorrhagic Shock. NIH. Start Date: 2017. End Date: 2021.

1 2 >>

Awards and Honors

                                                                                            1. USPTO. Patent application issued. Date: 2015.  

                                                                                            2. Journal of Pharmaceutical Sciences. Article selected as a featured research paper. Date: 2015.  

                                                                                            3. Robert Glenn Rapp Foundation. Presidential Professor . Date: 2013.  

                                                                                            4. Sandra K and David L Gilliland Chair in Nuclear Pharmacy . Date: 2012.  


                                                                                            1.  Degree: Ph D. Sanjay Gandhi Postgraduate Institute of Medical Sciences . Date: 1994.  

                                                                                            2.  Degree: M. Pharm.. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1990.  

                                                                                            3.  Degree: B. Pharm. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1988.